fenofibrate trial summary

All chronical situations: 3 trials - FIELD - DAIS - ACCORD lipid

No demonstrated result

suggested Non fatal MI by 24% (not demonstrated)

Endpoint	TE [95% CI]	p val	I2	n	k	trials
Venous thromboembolism	1.50 [1.13 2.00]	p=0.04	0	9795	1	FIELD,
cardiovascular events	0.90 [0.80 1.01]	p=1.00	0	9795	1	FIELD,
Cardiovascular death	1.10 [0.86 1.41]	p=1.00	0	9795	1	FIELD,
stroke (fatal and non fatal)	0.90 [0.73 1.12]	p=1.00	0	9795	1	FIELD,
Coronary event	0.88 [0.74 1.03]	p=1.00	0	10213	2	FIELD,DAIS,
Coronary death and non fatal MI	0.89 [0.75 1.06]	p=1.00	0	9795	1	FIELD,
Coronary death	1.18 [0.90 1.57]	p=1.00	0	9795	1	FIELD,
cardiac death	1.16 [0.88 1.52]	p=1.00	0	10213	2	FIELD,DAIS,
MACE	no data
Non fatal MI	0.76 [0.62 0.94]	p=0.04	0	9795	1	FIELD,
All cause death	1.09 [0.94 1.27]	p=1.00	0	10213	2	FIELD,DAIS,
non cardiovascular death	0.51 [0.09 2.81]	p=1.00	0	418	1	DAIS,
Fatal stroke	no data
Haemmorhagic stroke	no data
new-onset diabetes	no data
Death from cancer	1.14 [0.91 1.42]	p=1.00	0	9795	1	FIELD,
Rhabdomyolysis	3.00 [0.31 28.88]	p=1.00	0	9795	1	FIELD,
Myopathy	2.00 [0.18 22.09]	p=1.00	0	9795	1	FIELD,
Cancer	no data
Adverse events	1.58 [0.95 2.65]	p=1.00	0	9795	1	FIELD,

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

No demonstrated result

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

All type of patients: 3 trials - FIELD - DAIS - ACCORD lipid

No demonstrated result

suggested Non fatal MI by 24% (not demonstrated)

Endpoint	TE [95% CI]	p val	I2	n	k	trials
Venous thromboembolism	1.50 [1.13 2.00]	p=0.04	0	9795	1	FIELD,
cardiovascular events	0.90 [0.80 1.01]	p=1.00	0	9795	1	FIELD,
Cardiovascular death	1.10 [0.86 1.41]	p=1.00	0	9795	1	FIELD,
stroke (fatal and non fatal)	0.90 [0.73 1.12]	p=1.00	0	9795	1	FIELD,
Coronary event	0.88 [0.74 1.03]	p=1.00	0	10213	2	FIELD,DAIS,
Coronary death and non fatal MI	0.89 [0.75 1.06]	p=1.00	0	9795	1	FIELD,
Coronary death	1.18 [0.90 1.57]	p=1.00	0	9795	1	FIELD,
cardiac death	1.16 [0.88 1.52]	p=1.00	0	10213	2	FIELD,DAIS,
MACE	no data
Non fatal MI	0.76 [0.62 0.94]	p=0.04	0	9795	1	FIELD,
All cause death	1.09 [0.94 1.27]	p=1.00	0	10213	2	FIELD,DAIS,
non cardiovascular death	0.51 [0.09 2.81]	p=1.00	0	418	1	DAIS,
Fatal stroke	no data
Haemmorhagic stroke	no data
new-onset diabetes	no data
Death from cancer	1.14 [0.91 1.42]	p=1.00	0	9795	1	FIELD,
Rhabdomyolysis	3.00 [0.31 28.88]	p=1.00	0	9795	1	FIELD,
Myopathy	2.00 [0.18 22.09]	p=1.00	0	9795	1	FIELD,
Cancer	no data
Adverse events	1.58 [0.95 2.65]	p=1.00	0	9795	1	FIELD,

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

No demonstrated result

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

No demonstrated result

Endpoint	TE [95% CI]	p val	I2	n	k	trials
Venous thromboembolism	no data
cardiovascular events	0.90 [0.80 1.01]	p=1.00	0	9795	1	FIELD,
Cardiovascular death	1.10 [0.86 1.41]	p=1.00	0	9795	1	FIELD,
stroke (fatal and non fatal)	0.90 [0.73 1.12]	p=1.00	0	9795	1	FIELD,
Coronary event	0.88 [0.74 1.03]	p=1.00	0	10213	2	FIELD,DAIS,
Coronary death and non fatal MI	no data
Coronary death	no data
cardiac death	0.61 [0.14 2.59]	p=1.00	0	418	1	DAIS,
retinopathy	no data
vision loss	no data
MACE	no data
Non fatal MI	no data
All cause death	1.09 [0.94 1.27]	p=1.00	0	10213	2	FIELD,DAIS,
non cardiovascular death	0.51 [0.09 2.81]	p=1.00	0	418	1	DAIS,
Fatal stroke	no data
Haemmorhagic stroke	no data
new-onset diabetes	no data
Death from cancer	no data
Rhabdomyolysis	no data
Myopathy	no data
Cancer	no data
Adverse events	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

No demonstrated result

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

Diabetic patients with or withour hypercholesterolemia: 2 trials - FIELD - ACCORD lipid

No demonstrated result

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

No demonstrated result

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

Fenofibrate cholesterol lowering intervention